PA
JAZZ icon

Procyon Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Procyon Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13
Closed -$1K – 625
2020
Q2 		$1K Sell
13
-418
-97% -$46.2K ﹤0.01% 994
2020
Q1 		$43K Sell
431
-572
-57% -$74K 0.03% 353
2019
Q4 		$150K Buy
+1,003
New +$136K 0.09% 211

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Procyon Advisors's JAZZ Position: Q3 2020 in Review

Procyon Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 13 shares — an estimated $1K sold.

Procyon Advisors first reported a position in JAZZ in Q4 2019 and held it in 3 quarters. The position peaked at $150K in Q4 2019. 389 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

  • Procyon Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Procyon Advisors sold 13 Jazz Pharmaceuticals shares in Q3 2020, an estimated $1K.
  • Procyon Advisors first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Procyon Advisors's Jazz Pharmaceuticals position peaked at $150K in Q4 2019.
  • 389 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.